Results 221 to 230 of about 1,979,534 (305)
Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari +2 more
wiley +1 more source
Efficacy of Inhalational Ciprofloxacin (Apulmiq) in an NHP Model of Q Fever. [PDF]
Nelson M +8 more
europepmc +1 more source
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen +7 more
wiley +1 more source
Cannabinoid efficacy for pain: dose, chronicity and route. [PDF]
Ellioff KJ +4 more
europepmc +1 more source
Aim Many women take medications during pregnancy. However, the risk to the fetus from most medications is uncertain. Congenital anomalies are one of the leading causes of infant death and contribute to long‐term disability. Signal detection methods can be used to systematically identify possible medication–anomaly associations that require further ...
Hannah Johnson +22 more
wiley +1 more source
A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy. [PDF]
Diao D +6 more
europepmc +1 more source
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl +14 more
wiley +1 more source
Inhalable bacteriophage endolysins: a novel therapeutic strategy for drug-resistant bacterial pulmonary infections - a comprehensive review. [PDF]
Ding D +7 more
europepmc +1 more source
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz +7 more
wiley +1 more source
Aerosol inhalation of human IFN-α1b exhibits anti-RSV activity in mice and favorable pharmacokinetics/safety in cynomolgus monkeys. [PDF]
Yang M +7 more
europepmc +1 more source

